Award
NIH Reporter #1R41CA314908-01
Lead selection studies of novel antisense oligonucleotide for cancer immunotherapy
Recipient
National Cancer Institute (NCI), United States
Award Amount
$398,704.00
Ceiling
$398,704.00
Awarded
September 02, 2026
Identifier
1R41CA314908-01
Research project funded by the National Cancer Institute to study novel antisense oligonucleotide therapies combined with radiation for head and neck cancer immunotherapy.
Description
The project involves research on STAT3 signaling in head and neck cancer, proposing to combine radiation therapy with antisense oligonucleotide strategies. The project is funded by the National Cancer Institute, part of the NIH, and aims to support clinical translation of novel cancer immunotherapy strategies.